DGIdb - MITOMYCIN Drug Record

MITOMYCIN chembl:CHEMBL105 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MUTAMYCIN
NSC-26980
MYTOZYTREX
MITOMYCIN
MITOSOL
MITOMYCIN C
MITOZYTREX
MITOCIN-C
7-AMINO-9ALPHA-METHOXYMITOSANE
AMETYCINE
MITOSOL®
MITAMYCIN
MMC
drugbank:00305
rxcui:632
chemidplus:50-07-7
chembl:CHEMBL105
pubchem.compound:5746

Drug Info:

(2 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Monteagudo et al., 1990, Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome., Am. J. Hematol.
Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol
Kołaczkowska et al., 1998, [The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer]., Pneumonol Alergol Pol
van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.
Villarroel et al., 2011, Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer., Mol. Cancer Ther.

MITOMYCIN PALB2

Interaction Score: 3.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21135251

Sources:
CIViC
MITOMYCIN FANCC

Interaction Score: 2.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16243825

Sources:
CIViC
MITOMYCIN VWF

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2104558

Sources:
NCI
MITOMYCIN BGLAP

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9857648

Sources:
NCI
MITOMYCIN TP53

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14514923

Sources:
CIViC
MITOMYCIN CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MITOMYCIN CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MITOMYCIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MITOMYCIN CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MITOMYCIN CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MITOMYCIN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
MITOMYCIN AR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

NCI: MITOMYCIN

Version: 14-September-2017

Alternate Names:

C1820 NCI drug code

C663 NCI drug code

Drug Info:

Publications:

Monteagudo et al., 1990, Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome., Am. J. Hematol.

Kołaczkowska et al., 1998, [The effect of chemotherapy on bone metabolism in patients with non-small cell lung cancer]., Pneumonol Alergol Pol

DTC: MITOMYCIN
- Version: 02-September-2020
Alternate Names:

CHEMBL105 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

CIViC: MITOMYCIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

van der Heijden et al., 2005, In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor., Clin. Cancer Res.

Villarroel et al., 2011, Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer., Mol. Cancer Ther.

Bataille F et al., 2003, Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer., Mol Pathol

TTD: Mitomycin
- Version: 2020.06.01
Alternate Names:

D0Y0GH TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL105
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: mitomycin
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

MITOMYCIN Drug Record

MITOMYCIN chembl:CHEMBL105 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21135251

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16243825

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2104558

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9857648

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14514923

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

NCI: MITOMYCIN

Alternate Names: C1820 NCI drug code C663 NCI drug code

Drug Info:

DTC: MITOMYCIN

Alternate Names: CHEMBL105 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

CIViC: MITOMYCIN

Alternate Names:

Drug Info:

TTD: Mitomycin

Alternate Names: D0Y0GH TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL105

Alternate Names:

Drug Info:

Publications:

PharmGKB: mitomycin

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
21135251

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
16243825

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
2104558

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9857648

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14514923

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

C1820 NCI drug code

C663 NCI drug code

Alternate Names:

CHEMBL105 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D0Y0GH TTD Drug ID